ANI Pharmaceuticals, Inc. launches generic Pimozide tablets with 180-day exclusivity, targeting a $3.1M U.S. market.
Written By: Pharmacally Medical News Desk
ANI Pharmaceuticals, Inc. has announced the launch of its generic version of Pimozide tablets in 1 mg and 2 mg strengths, marking another step in the company’s strategy to expand its portfolio of niche generic products.
The newly launched product is a generic equivalent of Orap, a reference listed drug used primarily in the treatment of certain neurological and psychiatric conditions. ANI’s version will enter the U.S. market with 180-day Competitive Generic Therapy (CGT) exclusivity, providing the company a temporary advantage with limited direct competition.
Nikhil Lalwani, President and CEO of ANI Pharmaceuticals, said the launch reflects the company’s continued focus on bringing less competitive, high-value generic medicines to market. He emphasized the importance of expanding access to affordable treatment options for patients while strengthening the company’s commercial portfolio.
According to IQVIA data, U.S. annual sales for pimozide tablets are estimated at approximately $3.1 million based on February 2026 moving annual totals. While relatively modest in size, the market represents a targeted opportunity aligned with ANI’s strategy of pursuing specialized and limited-competition generics.
Reference
